ArticleNature immunology2021
Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Open access · hybridAbstract read
In one paragraph
Article in Nature immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 63 citations in OpenAlex.
- Functional and structural basis of Omicron BA.3.2.1 spike.Cell reports · 2026Article
- Broad Neutralizing Antibodies Against SARS-CoV-2: Current Progress and Engineering Strategies.Viruses · 2026Review
- Fc-engineered antibodies enhance protection against SARS-CoV-2 lung infection and inflammation.mBio · 2026Article
- Broad Neutralizing Activity of Monoclonal Antibodies Against the Omicron Variants Isolated From Patients With Early Severe Acute Respiratory Syndrome Coronavirus-2.Journal of medical virology · 2026Article
- Human antibody targeting of coronavirus spike S2 subunit is associated with protection mediated by Fc effector functions.Journal of virology · 2025Article
- Enhanced antibody response to the conformational non-RBD regionEmerging microbes & infections · 2025Article
- Article
- High-throughput multiplexed serology via the mass-spectrometric analysis of isotopically barcoded beads.Nature biomedical engineering · 2025Article
- Discovery of Synergistic Broadly Neutralizing Antibodies Targeting Non-Dominant Epitopes on SARS-CoV-2 RBD and NTD.Vaccines · 2025Article
- Applications and insights from continuous dengue virus infection in a stable cell line.Frontiers in immunology · 2025Article
- Structural Immunology of SARS-CoV-2.Immunological reviews · 2025Review
- SARS-CoV-2 ferritin nanoparticle vaccines produce hyperimmune equine sera with broad sarbecovirus activity.iScience · 2024Article
- Protective Non-neutralizing anti-N-terminal Domain mAb Maintains Fc-mediated Function against SARS-COV-2 Variants up to BA.2.86-JN.1 with Superfluous In Vivo Protection against JN.1 Due to Attenuated Virulence.Journal of immunology (Baltimore, Md. : 1950) · 2024Article
- Single-molecule imaging reveals allosteric stimulation of SARS-CoV-2 spike receptor binding domain by host sialic acid.Science advances · 2024Article
- Comprehensive Overview of Broadly Neutralizing Antibodies against SARS-CoV-2 Variants.Viruses · 2024Review
- Bispecific antibodies with broad neutralization potency against SARS-CoV-2 variants of concern.bioRxiv : the preprint server for biology · 2024Article
- Two antibodies show broad, synergistic neutralization against SARS-CoV-2 variants by inducing conformational change within the RBD.Protein & cell · 2024Article
- Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.Structure (London, England : 1993) · 2024Article
- Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.Nature communications · 2024Article
- An Immunoreceptor-Targeting Strategy with Minimalistic C3b Peptide Fusion Enhances SARS-CoV-2 RBD mRNA Vaccine Immunogenicity.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 8 institutions in 1 country.
Vincent Dussupt *Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-8579-6356
Rajeshwer S Sankhala *Emerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Letzibeth Mendez-RiveraU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Samantha M TownsleyU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Fabian SchmidtLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Lindsay WieczorekU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Kerri G LalEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Gina C DonofrioU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Ursula TranU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nathaniel D JacksonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-9654-6926
Weam I ZakyU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Michelle ZemilU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-1700-6658
Sarah R TritschMilken Institute School of Public Health, The George Washington University, Washington, DC, USA.
Wei-Hung ChenEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Elizabeth J MartinezEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Aslaa AhmedViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-3093-4982
Misook ChoeEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
William C ChangEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-4967-6426
Agnes HajduczkiEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Ningbo JianU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Caroline E PetersonEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Phyllis A ReesEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Magdalena RutkowskaLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
Bonnie M SlikeU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-4132-4637
Christopher N SelverianIntegral Molecular, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1047-4336
Isabella SwaffordU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0001-8638-2772
I-Ting TengVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.
Paul V ThomasEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Tongqing ZhouVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-3935-4637
Clayton J SmithNCI, NIH, Bethesda, MD, USA.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0002-5696-0268
Peter D KwongVaccine Research Center, NIAID, NIH, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-3560-232X
Morgane RollandU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-3650-8490
Edgar DavidsonIntegral Molecular, Philadelphia, PA, USA.
Benjamin J DoranzIntegral Molecular, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-8245-3083
Christopher N MoresMilken Institute School of Public Health, The George Washington University, Washington, DC, USA.ORCID http://orcid.org/0000-0001-6678-9049
Theodora HatziioannouLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
William W ReileyTrudeau Institute, Saranac Lake, NY, USA.
Paul D BieniaszLaboratory of Retrovirology, The Rockefeller University, New York, NY, USA.ORCID http://orcid.org/0000-0002-2368-3719
Dominic Paquin-ProulxU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0003-1407-3414
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Victoria R PolonisU.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
Nelson L MichaelCenter of Infectious Disease Research, Walter Reed Army Institute of Research, Silver Spring, MD, USA.ORCID http://orcid.org/0000-0001-5882-5548
Kayvon ModjarradEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA.
M Gordon JoyceEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA. gjoyce@eidresearch.org.ORCID http://orcid.org/0000-0002-6808-7232
Shelly J KrebsEmerging Infectious Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, MD, USA. skrebs@hivresearch.org.ORCID http://orcid.org/0000-0003-1136-1760
Henry M. Jackson Foundation · USWalter Reed Army Institute of Research · USIntegral Molecular (United States) · USRockefeller University · USMilken Institute · USHoward Hughes Medical Institute · USNational Institutes of Health · USTrudeau Institute · US
Funding
User Training and OutreachP30GM124165 · NIGMS · CORNELL UNIVERSITY · PI STEVEN E EALICK · 2018 to 2026
$34.2MOvercoming Host Restriction Factors to Develop Better Animal Models for HIV/AIDS.R01AI078788 · NIAID · ROCKEFELLER UNIVERSITY · PI HATZIIOANNOU, THEODORA · 2008 to 2021
$9.3MRNA Protein interactions in HIV-1 replicationR01AI050111 · NIAID · ROCKEFELLER UNIVERSITY · PI BIENIASZ, PAUL D. · 2001 to 2021
$7.9MB-Cell Epitope Discovery and Mechanisms of Antibody Protection for ZIKV, MARV, VEEV Envelope Proteins 75N93019C00073 · NIAID · INTEGRAL MOLECULAR · PI DORANZ, BENJAMIN · 2019 to 2023
$7.5MEvaluation of Antibody Responses Elicited by Zika Vaccination in Flavivirus-naïve and -experienced IndividualsR01AI155983 · NIAID · HENRY M. JACKSON FDN FOR THE ADV MIL/MED · PI Vincent Dussupt · 2021 to 2026
$4.2MPixel Array Detector for Macromolecular CrystallographyS10OD021527 · OD · CORNELL UNIVERSITY · PI EALICK, STEVEN E · 2016 to 2016
$2.0MNIAID NIH HHS 75N93019C00073NIAID NIH HHS R01 AI050111NIAID NIH HHS R01 AI078788NIAID NIH HHS R01 AI155983NIGMS NIH HHS P30 GM124165NIH HHS S10 OD021527
Abstract
Prevention of viral escape and increased coverage against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern require therapeutic monoclonal antibodies (mAbs) targeting multiple sites of vulnerability on the coronavirus spike glycoprotein. Here we identify several potent neutralizing antibodies directed against either the N-terminal domain (NTD) or the receptor-binding domain (RBD) of the spike protein. Administered in combinations, these mAbs provided low-dose protection against SARS-CoV-2 infection in the K18-human angiotensin-converting enzyme 2 mouse model, using both neutralization and Fc effector antibody functions. The RBD mAb WRAIR-2125, which targets residue F486 through a unique heavy-chain and light-chain pairing, demonstrated potent neutralizing activity against all major SARS-CoV-2 variants of concern. In combination with NTD and other RBD mAbs, WRAIR-2125 also prevented viral escape. These data demonstrate that NTD/RBD mAb combinations confer potent protection, likely leveraging complementary mechanisms of viral inactivation and clearance.
Indexed as
Amino Acid SequenceAnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralBinding SitesCOVID-19Disease Models, AnimalDose-Response Relationship, DrugEpitope MappingEpitopesHumansMice, TransgenicNeutralization TestsProtein BindingProtein ConformationAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesSpike Glycoprotein, Coronavirus
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.